Hans T. Schambye, CEO of Galecto, Inc. ($GLTO), made two open market sales of GLTO stock in the past year, totaling $17,450. His most recent sale occurred on January 2, 2026. These transactions rank 11,098th among 11,678 insiders by sale value, well below the average of $8.6 million across about 6.4 sales per insider. He recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | S | Common Stock | 700 | $21.38 | 4,682.0000 | 1,327,212 | 13.01% | 0.05% |
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | M | Common Stock | 1360 | $0.00 | 5,382.0000 | 1,327,212 | 33.81% | 0.10% |
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | M | Restricted Stock Units | 1360 | $0.00 | 2,640.0000 | 1,327,212 | 34.00% | 0.10% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | M | Common Stock | 1360 | $0.00 | 4,757.0000 | 1,322,359 | 40.04% | 0.10% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | S | Common Stock | 735 | $3.38 | 4,022.0000 | 1,322,359 | 15.45% | 0.06% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | M | Restricted Stock Units | 1360 | $0.00 | 4,000.0000 | 1,322,359 | 25.37% | 0.10% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | S | Common Stock | 1341 | $5.60 | 3,397.0000 | 0 | 28.30% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | M | Common Stock | 2640 | $0.00 | 4,738.0000 | 0 | 125.83% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | M | Restricted Stock Units | 2640 | $0.00 | 5,360.0000 | 0 | 33.00% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | A | Stock Option (right to buy) | 16400 | $0.00 | 16,400.0000 | 0 | 9999.99% | 0.00% |
| Oct. 9, 2024 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | A | Stock Option (right to buy) | 44100 | $0.00 | 44,100.0000 | 0 | 9999.99% | 0.00% |
| Jan. 3, 2024 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | A | Restricted Stock Units | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 4, 2023 | Damora Therapeutics, Inc. | $DMRA | Schambye Hans T. | Chief Executive Officer | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 0 | 9999.99% | 0.00% |